The mechanisms by which STZ induces AD development are not fully understood, but it has been proposed that this compound can enter neurons through GLUT2 and affect the insulin receptor, thereby improving the GSK3 pathway [89]. Here, SLC2A2 is linked to Alzheimer disease.